![BioCentury This Week](https://static.mytuner.mobi/media/podcasts/225/biocentury-this-week.jpg)
BioCentury製作的BioCentury This Week
BioCentury
分类: 科學與醫學
新增至我的清單
听听最后一集:
In this year’s series of Back to School essays, BioCentury’s editors ask whether the era of human first, causal biology and personalized medicine can reshape drug discovery to solve the weakest link in biotech — translation to the clinic. On a special edition of the BioCentury This Week podcast, the three authors of BioCentury’s 32nd Back to School edition, Editor in Chief Simone Fishburn, Executive Editor Selina Koch, and Executive Director of Biopharma Intelligence Lauren Martz, discuss how...
以前的剧集
-
260 - Ep. 251 - Eyes on the target: a Back to School Overview Fri, 06 Sep 2024
-
259 - Ep. 250 - Biosecure, Priority Review Vouchers & Target Discovery Wed, 04 Sep 2024
-
258 - Ep. 249 - Biotech IPO Buzz, Pharma Deal Trends, Washington Update Mon, 26 Aug 2024
-
257 - Ep. 248 - Grand Rounds Preview: Eyes on the Target Thu, 22 Aug 2024
-
256 - Ep. 247 - Drug Pricing, Psychedelic Setback & Back to School Mon, 19 Aug 2024
-
255 - Ep. 246 - Wilson’s Vision for Gene Therapy. Plus: Korea Biotech & Grand Rounds Mon, 12 Aug 2024
-
254 - Ep. 245 - Biotech-Academia Deals, Leqembi's Latest, Wilson Moves On Mon, 05 Aug 2024
-
253 - Ep. 244 - Leqembi's Thumbs-Down in Europe. Plus: Perioperative Cancer, Pediatric Review Vouchers Mon, 29 Jul 2024
-
252 - Ep. 243 - Radiopharma Alpha Emitters, AZ’s Galbraith and LNPs Mon, 22 Jul 2024
-
251 - Ep. 242 - 3Q Markets Preview, Washington Update, Lisa Burns Mon, 15 Jul 2024
-
250 - Ep. 241 - U.K. Biopharma on the Move. Plus: IRA, Biosecure Mon, 08 Jul 2024
-
249 - Ep. 240 - Chevron Ruling's Impact. Plus: Tumor Targets, Lurie Winner Mon, 01 Jul 2024
-
248 - Ep. 239 - Rare Disease Spotlight: MPS & DMD Mon, 24 Jun 2024
-
247 - Ep. 238 - Biosecure Act: The Impact & What's Ahead Thu, 20 Jun 2024
-
246 - Ep. 237- Pandemic Prep Problems, Reverse Mergers, Alzheimer’s & SCOTUS Mon, 17 Jun 2024
-
245 - Ep. 236 - BIO Wrap: Biosecure, Japan & Nxera, Radiopharma Thu, 13 Jun 2024
-
244 - Ep. 235 - Psychedelic Setback, FDA's Platform Play & ASCO Innovations Mon, 10 Jun 2024
-
243 - Ep. 234 - Biotech M&A, Biosecure Expands & ASCO Update Mon, 03 Jun 2024
-
242 - Ep. 233 - ASCO Preview, Rare Diseases & Biogen M&A Tue, 28 May 2024
-
241 - Ep. 232 - Shake up at BIO. Plus: ASGCT highlights, new IPF & obesity data Mon, 20 May 2024
-
240 - Bonus Content - Derek Lowe Unplugged: AI; Biosecure; FDA, Abortion & SCOTUS; and more Thu, 16 May 2024
-
239 - Ep. 231 - Biosecure Revised. Plus: Venture Rounds, Deals of Note Mon, 13 May 2024
-
238 - Bonus Content - Ysios' Karen Wagner: How Europe's Biotechs Can Rise Above the Noise Thu, 09 May 2024
-
237 - Ep. 230 - Bio€quity Europe 2024 Preview Wed, 08 May 2024
-
236 - Ep. 229 - ASGCT Preview, Accelerated Approval Plus: The Latest in Biosecure Mon, 06 May 2024
-
235 - Ep. 228 - Energizing Gene Therapy. Plus: AI Newco, Ono-Deciphera Mon, 29 Apr 2024
-
234 - Ep. 227 - Defending Accelerated Approval. Plus: Endpoint Innovation & AIM Amiss Mon, 22 Apr 2024
-
233 - Ep. 226 - Vertex’s Alpine Buy, Goldman’s Venture & IRA Tea Leaves Mon, 15 Apr 2024
-
232 - Ep. 225 - 2Q Markets Preview & AACR Takeaways Mon, 08 Apr 2024
-
231 - Ep. 224 - Biotech IPOs, Avalon & FDA at SCOTUS Mon, 01 Apr 2024
-
230 - Ep. 223 - Biosecure, Bruce Booth & Ultrarare Drugs Mon, 25 Mar 2024
-
229 - Ep. 222 - Crowley’s Vision for BIO, Plus: MASH & CAR Ts Mon, 18 Mar 2024
-
228 - Ep. 221 - China Biocontroversy, Plus: Diversity Matters Mon, 11 Mar 2024
-
227 - Ep. 220 - Biotech’s Financing Flurry & Distillery Spotlight Mon, 04 Mar 2024
-
226 - Ep. 219 - East-West Summit Preview Tue, 27 Feb 2024
-
225 - Ep. 218 - Bob Nelsen Insights, TL1A, Rare Diseases Mon, 26 Feb 2024
-
224 - Ep. 217 - Safer CAR Ts & World’s First TIL Therapy Tue, 20 Feb 2024
-
223 - Ep. 216 - Anti-China Biotech Policy: Biosecure & Beyond Thu, 15 Feb 2024
-
222 - Ep. 215 - ADCs, Psychedelics & IPOs Mon, 12 Feb 2024
-
221 - Ep. 214 - BMS’s Patent Cliff, Congress Targets China Biotech Mon, 05 Feb 2024
-
220 - Ep. 213 - Biotech IPOs & IL-18 Momentum Mon, 29 Jan 2024
-
219 - Ep. 212 - 2024 Buyside View & Arnold Ventures' Impact Mon, 22 Jan 2024
-
218 - Ep. 211 - 2024 Markets Preview, Woodcock's Legacy Tue, 16 Jan 2024
-
217 - Ep. 210 - J.P. Morgan Healthcare Conference Wrap Fri, 12 Jan 2024
-
216 - Ep. 209 - Biotech M&A, Innovation, Public Policy in 2024 Thu, 04 Jan 2024
-
215 - Ep. 208 - XBI Rally, ASH Highlights & '24 Picks Mon, 18 Dec 2023
-
214 - Ep. 207 - Sickle Cell, AbbVie Deals, BIO CEO, March-in Mon, 11 Dec 2023
-
213 - Ep. 206 - Roche, AbbVie Deals; Plus: FDA & CAR T Mon, 04 Dec 2023
-
212 - Ep. 205 - Radiotherapy Deep Dive; Plus: Congress, BioNTech Mon, 27 Nov 2023
-
211 - Ep. 204 - First CRISPR Approval & IRA’s Lost Orphans Mon, 20 Nov 2023
显示更多剧集
5